申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP2020411A1
公开(公告)日:2009-02-04
Disclosed is an anti-coagulant which has extremely excellent inhibitory effect on FXa and an extremely poor inhibitory effect on hERG channel, and can be administered through the oral route. Specifically, dislosed is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof.
本发明公开了一种抗凝血剂,它对 FXa 的抑制效果极佳,而对 hERG 通道的抑制效果极差,可通过口服途径给药。具体而言,公开了一种由式(I)代表的化合物或其药学上可接受的盐。